Cefazolin Noridem
First-generation cephalosporin antibiotic for injection and infusion
Quick Facts about Cefazolin Noridem
Key Takeaways
- Gold standard for surgical prophylaxis: Cefazolin is the most recommended antibiotic for perioperative infection prevention in clean and clean-contaminated surgeries worldwide
- Administered only by healthcare professionals: This medicine is given as an injection or infusion in a hospital or clinical setting – it cannot be taken orally
- Excellent Gram-positive coverage: Highly effective against methicillin-susceptible Staphylococcus aureus (MSSA) and Streptococcus species
- Penicillin allergy caution: Cross-reactivity with penicillin is low (1–2%) but patients with severe penicillin anaphylaxis should generally avoid cefazolin
- Dose adjustment in kidney disease: Patients with impaired renal function require dose reduction as cefazolin is primarily eliminated through the kidneys
What Is Cefazolin Noridem and What Is It Used For?
Cefazolin Noridem is a first-generation cephalosporin antibiotic that kills bacteria by disrupting their cell wall synthesis. It is primarily used for surgical prophylaxis and treatment of infections caused by susceptible Gram-positive organisms, including skin, soft tissue, bone, joint, and urinary tract infections.
Cefazolin belongs to the beta-lactam family of antibiotics and is classified as a first-generation cephalosporin. First introduced in the 1970s, it has remained one of the most widely used parenteral antibiotics in clinical practice. Its popularity stems from its excellent activity against common Gram-positive pathogens, favorable safety profile, low cost, and well-established efficacy in surgical prophylaxis.
The active substance, cefazolin (administered as cefazolin sodium), works by binding to penicillin-binding proteins (PBPs) on the bacterial cell wall. This inhibits the final transpeptidation step of peptidoglycan synthesis, which is essential for maintaining the structural integrity of the bacterial cell wall. Without a functional cell wall, the bacterium undergoes lysis and death. This mechanism makes cefazolin bactericidal rather than merely bacteriostatic.
Cefazolin demonstrates excellent activity against a range of clinically important pathogens. It is highly effective against methicillin-susceptible Staphylococcus aureus (MSSA), coagulase-negative staphylococci, Streptococcus pyogenes (Group A streptococcus), Streptococcus agalactiae (Group B streptococcus), and Streptococcus pneumoniae. It also has moderate activity against certain Gram-negative organisms including Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis. However, it is not effective against methicillin-resistant Staphylococcus aureus (MRSA), Enterococcus species, Pseudomonas aeruginosa, or most anaerobic bacteria.
Approved Indications
Cefazolin Noridem is approved for the treatment and prevention of the following infections when caused by susceptible organisms:
- Surgical prophylaxis: Prevention of surgical site infections in clean and clean-contaminated procedures, including cardiac, orthopedic, abdominal, vascular, and cesarean section surgeries
- Skin and soft tissue infections: Cellulitis, wound infections, and abscesses caused by susceptible staphylococci and streptococci
- Bone and joint infections: Osteomyelitis and septic arthritis, particularly when caused by MSSA
- Urinary tract infections: Complicated and uncomplicated UTIs caused by susceptible organisms such as E. coli and K. pneumoniae
- Endocarditis: Native valve endocarditis caused by susceptible streptococci and MSSA
- Septicemia/bloodstream infections: When caused by susceptible organisms
- Respiratory tract infections: Including pneumonia caused by susceptible S. pneumoniae, S. aureus, and K. pneumoniae
- Biliary tract infections: Cholecystitis and cholangitis caused by susceptible organisms
According to guidelines from the Infectious Diseases Society of America (IDSA), the American Society of Health-System Pharmacists (ASHP), and the World Health Organization (WHO), cefazolin is recommended as the first-line agent for surgical prophylaxis in most procedures. Its advantages include a favorable spectrum of activity covering the most common surgical site infection pathogens (primarily S. aureus and streptococci), a long serum half-life allowing single-dose prophylaxis for shorter procedures, excellent tissue penetration, a well-established safety profile, and low cost.
What Should You Know Before Receiving Cefazolin Noridem?
Before receiving cefazolin, inform your healthcare provider about all allergies (especially to penicillin or cephalosporins), kidney problems, gastrointestinal conditions, and all medications you are taking. Cefazolin is contraindicated in patients with known severe hypersensitivity to cephalosporin antibiotics.
As with all antibiotics, cefazolin should only be used when there is a genuine clinical need. Unnecessary or inappropriate use of antibiotics contributes to the growing problem of antimicrobial resistance, which the World Health Organization has identified as one of the top ten global public health threats. Your healthcare provider will assess whether cefazolin is the most appropriate antibiotic for your specific situation.
Contraindications
Cefazolin Noridem must not be used in the following situations:
- Known severe hypersensitivity: Patients with a documented history of anaphylaxis or severe allergic reaction to cefazolin or any other cephalosporin antibiotic must not receive this medication
- Hypersensitivity to excipients: Patients with known allergy to any of the inactive ingredients in the formulation
Warnings and Precautions
Special care and close monitoring are needed in the following situations:
- Penicillin allergy: There is a risk of cross-reactivity between penicillins and cephalosporins. While the cross-reactivity rate for first-generation cephalosporins is estimated at only 1–2% (much lower than the historically quoted 10%), patients with a history of severe penicillin allergy (anaphylaxis, angioedema, severe urticaria) should generally avoid cefazolin or receive it only under close medical supervision with resuscitation equipment available
- Renal impairment: Cefazolin is primarily excreted by the kidneys. Patients with reduced kidney function (creatinine clearance below 55 mL/min) require dose adjustments to prevent drug accumulation and potential toxicity, including seizures
- Clostridioides difficile infection: Antibiotic use can disrupt normal gut flora and lead to Clostridioides difficile-associated diarrhea (CDAD), ranging from mild diarrhea to fatal pseudomembranous colitis. If significant diarrhea develops during or after treatment, CDAD should be considered
- Seizure risk: High doses of cefazolin, particularly in patients with renal impairment, may lower the seizure threshold. Dose adjustments are essential in these patients
- Superinfection: Prolonged use may lead to overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, appropriate measures should be taken
- Coagulation disorders: Cefazolin may rarely interfere with prothrombin activity, particularly in patients with vitamin K deficiency, liver disease, or poor nutritional status
Pregnancy and Breastfeeding
Cefazolin crosses the placenta and is found in fetal tissues. It is classified as FDA pregnancy category B, indicating that animal reproduction studies have not demonstrated fetal risk, though adequate controlled studies in pregnant women are lacking. Cefazolin is generally considered one of the safer antibiotics during pregnancy and is routinely used for surgical prophylaxis during cesarean sections. The American College of Obstetricians and Gynecologists (ACOG) recommends cefazolin as the preferred agent for cesarean section prophylaxis.
Cefazolin is excreted in breast milk in small amounts. The concentrations in breast milk are typically very low and are generally considered compatible with breastfeeding. However, monitoring the breastfed infant for potential effects such as diarrhea, candidiasis, or allergic sensitization is advisable. Always discuss the risks and benefits with your healthcare provider before receiving cefazolin during pregnancy or while breastfeeding.
Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving cephalosporin antibiotics. If an allergic reaction occurs during cefazolin administration, the infusion must be stopped immediately and appropriate emergency treatment initiated. Healthcare facilities administering cefazolin should have resuscitation equipment and epinephrine readily available.
How Does Cefazolin Noridem Interact with Other Drugs?
Cefazolin can interact with anticoagulants (increasing bleeding risk), probenecid (increasing cefazolin blood levels), aminoglycoside antibiotics (potentially increasing kidney toxicity risk), and certain laboratory tests. Always inform your healthcare team about all medications you are taking.
Drug interactions with cefazolin are relatively few compared to many other antibiotics, which contributes to its favorable clinical profile. However, several important interactions should be considered by the prescribing healthcare professional. The following table summarizes the most clinically relevant drug interactions:
| Interacting Drug | Type | Effect | Clinical Recommendation |
|---|---|---|---|
| Warfarin / Oral anticoagulants | Major | Cephalosporins may enhance anticoagulant effect, increasing risk of bleeding by disrupting vitamin K-producing gut flora | Monitor INR closely; adjust anticoagulant dose if needed |
| Probenecid | Major | Inhibits renal tubular secretion of cefazolin, resulting in higher and prolonged serum concentrations | Concurrent use may require dose adjustment; monitor for toxicity |
| Aminoglycosides (gentamicin, tobramycin) | Moderate | Potential synergistic antibacterial effect but combined nephrotoxicity risk; physical incompatibility when mixed in same IV line | Monitor renal function closely; administer separately through different IV lines |
| Loop diuretics (furosemide) | Moderate | May increase the risk of nephrotoxicity when combined with cephalosporins | Monitor renal function; ensure adequate hydration |
| Heparin | Minor | Theoretical increase in bleeding risk; physical incompatibility in IV solutions | Do not mix in same IV line; monitor for bleeding |
Laboratory Test Interference
Cefazolin can interfere with several common laboratory tests, which healthcare providers should be aware of:
- False-positive urine glucose tests: Cefazolin may cause false-positive results with copper-reduction urine glucose tests (e.g., Benedict's solution, Clinitest). Enzyme-based glucose tests (glucose oxidase method) are not affected and should be used instead
- False-positive direct Coombs test: Cephalosporins, including cefazolin, can cause a positive direct antiglobulin (Coombs) test, which may interfere with cross-matching for blood transfusions. This does not indicate true hemolytic anemia in most cases
- Serum creatinine: Cefazolin may falsely elevate serum creatinine levels when measured by the Jaffe reaction method
What Is the Correct Dosage of Cefazolin Noridem?
Cefazolin dosage depends on the type and severity of infection, the patient's weight, and kidney function. For surgical prophylaxis in adults, the typical dose is 2 g IV given 30–60 minutes before incision. For treatment of infections, the usual adult dose is 1–2 g every 8 hours. Dose adjustment is required in patients with impaired kidney function.
Cefazolin Noridem is supplied as a powder that must be reconstituted before administration. It can be given as an intramuscular (IM) injection, a direct intravenous (IV) injection (over 3–5 minutes), or as an intravenous infusion (over 30–60 minutes). The choice of route and method depends on the clinical situation and the dose being administered. Only trained healthcare professionals should prepare and administer this medication.
Adults
| Indication | Dose | Frequency | Duration |
|---|---|---|---|
| Surgical prophylaxis | 2 g IV (3 g if >120 kg) | Single dose 30–60 min before incision; redose every 4 hours during prolonged surgery | Single dose or up to 24 hours post-op |
| Mild infections (UTI, skin) | 500 mg–1 g | Every 8 hours | 7–14 days (based on clinical response) |
| Moderate to severe infections | 1–2 g | Every 6–8 hours | As directed by physician |
| Severe, life-threatening infections (endocarditis, septicemia) | 2 g | Every 6–8 hours (max 12 g/day) | 4–6 weeks (endocarditis); as clinically indicated |
Children
For pediatric patients (aged 1 month and older), the recommended dose of cefazolin is 25–50 mg/kg/day divided into 3–4 doses (every 6–8 hours). For severe infections, the dose may be increased to 100 mg/kg/day. The total daily dose should not exceed the equivalent adult dose. For surgical prophylaxis in children, 30 mg/kg IV is given within 60 minutes before the surgical incision.
Neonates (under 1 month of age) have immature renal function and require special dosing considerations. Typical neonatal doses range from 25–50 mg/kg/day divided every 8–12 hours, depending on gestational and postnatal age. Neonatal dosing should always be guided by a pediatric infectious disease specialist or neonatologist.
Elderly
Elderly patients may have reduced renal function that is not reflected by serum creatinine levels alone. Dose adjustments should be based on calculated creatinine clearance rather than serum creatinine. In elderly patients with normal renal function, no specific dose adjustment is required. However, monitoring renal function during treatment is recommended, especially in those receiving concurrent nephrotoxic agents.
Dose Adjustment in Renal Impairment
| Creatinine Clearance (mL/min) | Dose Recommendation |
|---|---|
| >55 mL/min | Normal dose, no adjustment needed |
| 35–54 mL/min | Full dose every 8 hours (maximum) |
| 11–34 mL/min | 50% of normal dose every 12 hours |
| ≤10 mL/min | 50% of normal dose every 18–24 hours |
| Hemodialysis patients | Supplemental dose after each dialysis session (cefazolin is partially dialyzable) |
Missed Dose
Since cefazolin is administered by healthcare professionals in a clinical setting, missed doses are uncommon. If a scheduled dose is delayed, it should be administered as soon as possible. The subsequent dose schedule should be adjusted to maintain the appropriate dosing interval. Two doses should never be administered simultaneously to compensate for a missed dose. The healthcare team will monitor and manage the dosing schedule.
Overdose
Overdose with cefazolin may lead to pain, inflammation, and phlebitis at the injection site. Systemic overdose, particularly in patients with impaired renal function, can result in neurological symptoms including seizures, encephalopathy, tremors, and neuromuscular excitability. Overdose may also cause nausea, vomiting, epigastric distress, and hematuria. Treatment is primarily supportive. Hemodialysis can help remove cefazolin from the body, although it is only partially effective. There is no specific antidote.
What Are the Side Effects of Cefazolin Noridem?
Like all antibiotics, cefazolin can cause side effects, though not everyone experiences them. The most common side effects include gastrointestinal symptoms (diarrhea, nausea, vomiting) and injection site reactions. Serious but rare side effects include severe allergic reactions, Clostridioides difficile colitis, and blood disorders.
Cefazolin is generally well tolerated. Most side effects are mild, transient, and resolve after treatment is discontinued. However, certain adverse effects require immediate medical attention. The following classification is based on reported frequencies from clinical trials and post-marketing surveillance:
Common
- Diarrhea
- Nausea and vomiting
- Abdominal pain or discomfort
- Injection site pain, redness, or swelling
- Skin rash
- Oral or vaginal candidiasis (thrush)
Uncommon
- Urticaria (hives)
- Pruritus (itching)
- Drug fever
- Elevated liver enzymes (AST, ALT, alkaline phosphatase)
- Eosinophilia (elevated eosinophil count)
- Phlebitis or thrombophlebitis at IV site
- Headache and dizziness
Rare
- Anaphylaxis and severe allergic reactions
- Clostridioides difficile-associated diarrhea and pseudomembranous colitis
- Leukopenia, neutropenia, and thrombocytopenia
- Hemolytic anemia (positive Coombs test)
- Interstitial nephritis
- Seizures (particularly with renal impairment or high doses)
- Stevens-Johnson syndrome and toxic epidermal necrolysis
- Hepatitis and cholestatic jaundice
Signs of a severe allergic reaction: difficulty breathing, swelling of the face, lips, tongue or throat, severe skin rash with blistering, rapid heartbeat, or feeling faint. Also seek urgent care for severe or persistent diarrhea (which could indicate C. difficile infection), unusual bleeding or bruising, yellowing of the skin or eyes, or seizures.
The risk of side effects may be increased in patients with renal impairment (due to drug accumulation), elderly patients, those receiving prolonged therapy, and patients with a history of gastrointestinal disease, particularly colitis. If you experience any unexpected or troublesome symptoms during or after cefazolin treatment, inform your healthcare provider promptly.
How Should You Store Cefazolin Noridem?
Unopened vials of cefazolin powder should be stored below 25°C, protected from light. Once reconstituted, the solution should be used immediately or within a limited timeframe depending on the diluent and storage conditions. Storage and handling are managed by pharmacy and nursing staff.
Proper storage of cefazolin is essential to maintain its stability and efficacy. As this medication is administered in healthcare settings, storage and preparation are managed by pharmacy and nursing staff. The following guidelines apply:
- Unopened vials: Store below 25°C (77°F) in the original packaging to protect from light. Do not freeze the dry powder
- Reconstituted solution (refrigerated, 2–8°C): Generally stable for up to 24 hours, depending on the diluent used. Consult the specific product information for exact stability data
- Reconstituted solution (room temperature, ≤25°C): Should be used within 12 hours of preparation
- Visual inspection: Before administration, the reconstituted solution should be inspected for particulate matter and discoloration. The solution should appear pale yellow to yellow. Do not use if the solution is cloudy or contains visible particles
- Shelf life: Check the expiry date on the packaging. Do not use after the stated expiration date
Keep all medicines out of the sight and reach of children. Do not dispose of unused medication via household waste or wastewater. Return unused or expired medications to your pharmacy for proper disposal in accordance with local environmental regulations.
What Does Cefazolin Noridem Contain?
Each vial of Cefazolin Noridem contains cefazolin sodium equivalent to 1 g of cefazolin as the active ingredient. The powder contains no preservatives or additional excipients and must be reconstituted with a suitable diluent before administration.
Cefazolin Noridem is formulated as a white to off-white crystalline powder for reconstitution. The formulation is intentionally simple:
- Active ingredient: Cefazolin sodium, equivalent to 1 g cefazolin per vial. The sodium salt form improves water solubility and allows for parenteral administration
- Sodium content: Each 1 g vial contains approximately 48 mg (2.1 mmol) of sodium. This should be taken into account for patients on a sodium-restricted diet or receiving multiple doses
- No additional excipients: The powder contains no preservatives, buffers, or other inactive ingredients
Reconstitution
The powder must be dissolved before use. Compatible diluents for reconstitution include:
- Sterile Water for Injection
- 0.9% Sodium Chloride (Normal Saline)
- 5% Dextrose (Glucose) Solution
- Lactated Ringer's Solution (for infusion only)
For intramuscular injection, the powder is typically reconstituted with 2.5 mL of Sterile Water for Injection. For intravenous injection or infusion, larger volumes of compatible diluent are used. The exact volumes and concentrations depend on the intended route and method of administration. Always refer to the product's Summary of Product Characteristics (SmPC) for detailed reconstitution instructions.
Physical Properties
Cefazolin sodium is a white to off-white crystalline powder that is freely soluble in water. When reconstituted, the solution has a pH between 4.5 and 6.0. The molecular weight of cefazolin sodium is 476.5 g/mol (454.5 g/mol for cefazolin free acid). It has a characteristic chemical structure that includes a beta-lactam ring fused to a dihydrothiazine ring, which is the defining feature of the cephalosporin class.
Frequently Asked Questions
Cefazolin Noridem is a first-generation cephalosporin antibiotic used primarily for surgical prophylaxis (preventing infections during surgery) and treatment of infections caused by susceptible bacteria. Common indications include skin and soft tissue infections, bone and joint infections, urinary tract infections, endocarditis, septicemia, and respiratory tract infections. It is one of the most widely used antibiotics globally for perioperative infection prevention.
The risk of cross-reactivity between penicillin and first-generation cephalosporins like cefazolin is approximately 1–2%, which is much lower than historically believed. Patients with mild penicillin allergies (such as a non-severe rash) can often safely receive cefazolin under medical supervision. However, if you have experienced a severe allergic reaction to penicillin (anaphylaxis, severe urticaria, angioedema), cefazolin should generally be avoided. Always inform your healthcare provider about all drug allergies before treatment.
Cefazolin Noridem is given only by injection or infusion – it cannot be taken by mouth. It is administered either intravenously (into a vein) or intramuscularly (into a muscle) by trained healthcare professionals in a hospital or clinical setting. The powder must be reconstituted (dissolved) with a sterile solution before use. For surgical prophylaxis, it is typically given 30–60 minutes before the surgical incision to ensure adequate tissue concentrations at the time of the procedure.
The most commonly reported side effects include gastrointestinal symptoms such as diarrhea, nausea, and vomiting, as well as injection site reactions including pain, redness, and swelling. Skin rashes and oral or vaginal candidiasis (thrush) may also occur. These side effects are generally mild and resolve after treatment is completed. Serious side effects such as severe allergic reactions or Clostridioides difficile infection are rare but require immediate medical attention.
Cefazolin is generally considered one of the safer antibiotics for use during pregnancy (FDA category B). It is routinely used for surgical prophylaxis during cesarean sections, as recommended by the American College of Obstetricians and Gynecologists (ACOG). While cefazolin does cross the placenta and is excreted in small amounts in breast milk, adverse effects in the fetus or breastfed infant are uncommon. As with all medications during pregnancy, it should only be used when the potential benefit justifies the potential risk, as determined by your healthcare provider.
No. Cefazolin is not effective against methicillin-resistant Staphylococcus aureus (MRSA). MRSA produces an altered penicillin-binding protein (PBP2a) that has low affinity for all beta-lactam antibiotics, including cefazolin. If MRSA infection is suspected or confirmed, alternative antibiotics such as vancomycin, daptomycin, or linezolid should be used instead. Cefazolin remains highly effective against methicillin-susceptible S. aureus (MSSA) and is considered the agent of choice for MSSA bacteremia and endocarditis.
References
This article is based on the following peer-reviewed sources and international guidelines:
- Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. American Journal of Health-System Pharmacy. 2013;70(3):195-283. ASHP/IDSA/SIS/SHEA Guidelines.
- World Health Organization. Global Guidelines for the Prevention of Surgical Site Infection. 2nd edition. Geneva: WHO; 2018.
- European Medicines Agency. Cefazolin – Summary of Product Characteristics. EMA assessment report and product information.
- Baddour LM, Wilson WR, Bayer AS, et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications. Circulation. 2015;132(15):1435-1486. AHA Scientific Statement.
- Pichichero ME. A review of evidence supporting the American Academy of Pediatrics recommendation for prescribing cephalosporin antibiotics for penicillin-allergic patients. Pediatrics. 2005;115(4):1048-1057.
- Tamma PD, Aitken SL, Bonomo RA, et al. IDSA 2023 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clinical Infectious Diseases. 2023.
- British National Formulary (BNF). Cefazolin. National Institute for Health and Care Excellence (NICE). Updated 2024.
- American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 199: Use of Prophylactic Antibiotics in Labor and Delivery. Obstetrics & Gynecology. 2018;132(3):e103-e119.
- WHO Model List of Essential Medicines – 23rd List, 2023. Geneva: World Health Organization; 2023. Cefazolin listed as an essential antibiotic.
- Vardakas KZ, Trigkidis KK, Boukouvala E, Falagas ME. Clostridium difficile infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysis. International Journal of Antimicrobial Agents. 2016;48(1):1-10.
Editorial Team
This article was written and medically reviewed by the iMedic Medical Editorial Team, comprising specialists in infectious disease, clinical pharmacology, and hospital pharmacy.
iMedic Medical Editorial Team – specialists in infectious disease and clinical pharmacology with extensive experience in antimicrobial therapy and surgical prophylaxis protocols.
iMedic Medical Review Board – independent panel of board-certified physicians who review all content according to international guidelines (WHO, EMA, FDA, IDSA, BNF).
All medical information on iMedic is evidence-based and follows the GRADE framework for evaluating the quality of evidence. We have no commercial funding and no pharmaceutical company sponsorship. Our content is reviewed according to international medical standards and updated regularly to reflect the latest evidence. Read more about our editorial standards.